AR070560A1 - Formas cristalinas de acido 4-(4-(2-adamantilcarbamoil) -5-ter-butil-pirazol-1-il) benzoico 471 - Google Patents
Formas cristalinas de acido 4-(4-(2-adamantilcarbamoil) -5-ter-butil-pirazol-1-il) benzoico 471Info
- Publication number
- AR070560A1 AR070560A1 ARP090100364A ARP090100364A AR070560A1 AR 070560 A1 AR070560 A1 AR 070560A1 AR P090100364 A ARP090100364 A AR P090100364A AR P090100364 A ARP090100364 A AR P090100364A AR 070560 A1 AR070560 A1 AR 070560A1
- Authority
- AR
- Argentina
- Prior art keywords
- tit
- peaks
- crystalline form
- diffraction pattern
- following
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 229910016523 CuKa Inorganic materials 0.000 abstract 4
- 230000005855 radiation Effects 0.000 abstract 4
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- XWBXJBSVYVJAMZ-UHFFFAOYSA-N 4-[4-(2-adamantylcarbamoyl)-5-tert-butylpyrazol-1-yl]benzoic acid Chemical compound CC(C)(C)C1=C(C(=O)NC2C3CC4CC(C3)CC2C4)C=NN1C1=CC=C(C(O)=O)C=C1 XWBXJBSVYVJAMZ-UHFFFAOYSA-N 0.000 abstract 1
- 101100451537 Caenorhabditis elegans hsd-1 gene Proteins 0.000 abstract 1
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
También se describen su uso en la inhibicion de 11betaHSD1, procedimientos para prepararlas y composiciones farmacéuticas que las comprenden. Reivindicacion 1: Una forma cristalina de ácido 4-[4-(2-adamantilcarbamoil)-5-ter-butil- pirazol-1-il]benzoico que tiene un patron de difraccion por rayos X con picos en los siguientes valores 2-teta, medidos usando radiacion CuKa: 18,0 y 17,7°. Reivindicacion 4: Una forma cristalina de un compuesto tal como ha sido reivindicado en la reivindicacion 1 que tiene un patron de difraccion de polvo por rayos X con picos en los siguientes valores 2-teta usando radiacion CuKa: 18,0, 17,7, 18,4, 8,9, 20,5, 10,4, 21,9, 13,4, 27,6 y 16,7°. Reivindicacion 10: Una forma cristalina de un compuesto tal como se ha reivindicado en la reivindicacion 7 que tiene un patron de difraccion de polvo por rayos X con picos en los siguientes valores 2-teta medidos usando radiacion CuKa: 18,7, 11,7, 19,2, 7,8, 14,1, 14,9, 9,4, 15,6, 16,1 y 9,6°. Reivindicacion 16: Una forma cristalina tal como se ha reivindicado en la reivindicacion 13 que tiene un patron de difraccion de polvo por rayos X con picos en los siguientes valores 2-teta medidos usando radiacion CuKa: 16,2, 20,6, 17,7, 10,8, 15,5, 20,9, 26,1, 11,6, 26,7 y18,1°.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PK10808 | 2008-02-04 | ||
| PCT/GB2008/000454 WO2008099145A1 (en) | 2007-02-12 | 2008-02-11 | Pyrazole derivatives as 11-beta-hsd1 inhibitors |
| US8229308P | 2008-07-21 | 2008-07-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070560A1 true AR070560A1 (es) | 2010-04-21 |
Family
ID=42782026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100364A AR070560A1 (es) | 2008-02-04 | 2009-02-04 | Formas cristalinas de acido 4-(4-(2-adamantilcarbamoil) -5-ter-butil-pirazol-1-il) benzoico 471 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US7951833B2 (es) |
| EP (1) | EP2244705A1 (es) |
| JP (1) | JP2011510966A (es) |
| KR (1) | KR20100126306A (es) |
| CN (1) | CN101969946A (es) |
| AR (1) | AR070560A1 (es) |
| AU (1) | AU2009211215B2 (es) |
| CA (1) | CA2713409A1 (es) |
| MX (1) | MX2010008583A (es) |
| PE (1) | PE20091456A1 (es) |
| RU (1) | RU2010133483A (es) |
| SA (1) | SA109300090B1 (es) |
| TW (1) | TW200946506A (es) |
| UY (1) | UY31627A1 (es) |
| WO (1) | WO2009098501A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2443689C2 (ru) | 2005-11-21 | 2012-02-27 | Сионоги Энд Ко., Лтд. | ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К 11β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЕ 1 ТИПА |
| TW200827346A (en) * | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
| TW200836719A (en) | 2007-02-12 | 2008-09-16 | Astrazeneca Ab | Chemical compounds |
| ES2535317T3 (es) | 2007-05-18 | 2015-05-08 | Shionogi & Co., Ltd. | Derivado heterocíclico que contiene nitrógeno que tiene actividad inhibidora de la 11 beta-hidroxiesteroide deshidrogenasa de tipo 1 |
| SA109300090B1 (ar) * | 2008-02-04 | 2011-10-03 | استرازينيكا ايه بي | صور متبلرة جديدة من 4- [4- (2- أدامنتيل كربامويل) -5- ثلاثي- بيوتيل – بيرازول -1- يل] حمض بنزويك 471 |
| JP2011518216A (ja) * | 2008-04-22 | 2011-06-23 | アストラゼネカ アクチボラグ | 置換ピリミジン−５−カルボキサミド |
| JP2012516327A (ja) * | 2009-01-30 | 2012-07-19 | アストラゼネカ アクチボラグ | カルボキシ含有ピラゾールアミド化合物を製造するための新規な方法 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| AU2017348598B2 (en) * | 2016-10-28 | 2020-02-20 | Astrazeneca Ab | Crystalline form of (1R,2R)-2-[4-(3-methyl-1H-pyrazol-5-yl)benzoyl]-N- (4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3- yl)cyclohexanecarboxamide |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR66581B (es) * | 1978-02-21 | 1981-03-27 | Delalande Sa | |
| US7273868B2 (en) * | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
| EP1615698B1 (en) * | 2003-04-11 | 2010-09-29 | High Point Pharmaceuticals, LLC | New amide derivatives and pharmaceutical use thereof |
| AU2004265299B2 (en) | 2003-08-07 | 2008-05-01 | Merck & Co., Inc. | Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
| JP2007536369A (ja) | 2004-05-06 | 2007-12-13 | ファイザー・インク | プロリン及びモルホリン誘導体の新規化合物 |
| JP2008518903A (ja) | 2004-11-02 | 2008-06-05 | ファイザー・インク | 置換および非置換アダマンチルアミドの新規化合物 |
| WO2006106052A1 (en) * | 2005-04-05 | 2006-10-12 | F. Hoffmann-La Roche Ag | Pyrazoles |
| ATE435207T1 (de) | 2005-04-06 | 2009-07-15 | Hoffmann La Roche | Pyridin-3-carbonsäureamidderivate als cb1-inverse agonisten |
| EP1879881A2 (en) | 2005-04-14 | 2008-01-23 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
| EP1894919B1 (en) | 2005-06-07 | 2012-03-28 | Shionogi & Co., Ltd. | Heterocyclic compound having type i 11 beta hydroxysteroid dehydrogenase inhibitory activity |
| WO2006132436A1 (ja) | 2005-06-08 | 2006-12-14 | Japan Tobacco Inc. | 複素環化合物 |
| WO2007052843A1 (ja) | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物およびその用途 |
| RU2443689C2 (ru) | 2005-11-21 | 2012-02-27 | Сионоги Энд Ко., Лтд. | ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К 11β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЕ 1 ТИПА |
| RS54216B1 (sr) * | 2006-03-22 | 2015-12-31 | F. Hoffmann-La Roche Ag. | Pirazoli kao 11-beta-hsd-1 |
| WO2008012532A2 (en) | 2006-07-27 | 2008-01-31 | Astrazeneca Ab | : pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase |
| TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
| TW200836719A (en) * | 2007-02-12 | 2008-09-16 | Astrazeneca Ab | Chemical compounds |
| ES2535317T3 (es) | 2007-05-18 | 2015-05-08 | Shionogi & Co., Ltd. | Derivado heterocíclico que contiene nitrógeno que tiene actividad inhibidora de la 11 beta-hidroxiesteroide deshidrogenasa de tipo 1 |
| BRPI0814825A2 (pt) | 2007-07-17 | 2015-02-03 | Hoffmann La Roche | Composto, processo para a preparação do composto, composição farmacêutica que o compreende, seu uso e métodos para o tratamento ou profilaxia de diabetes, obesidade, distúrbios de alimentação ou dislipimedia e diabetes do tipo ii |
| MX2010005048A (es) * | 2007-11-06 | 2010-07-28 | Astrazeneca Ab | Acido 4-[4-(2-adamantilcarbamoil)-5-terc-butil-pirazol-1-il]benzoi c-465. |
| SA109300090B1 (ar) * | 2008-02-04 | 2011-10-03 | استرازينيكا ايه بي | صور متبلرة جديدة من 4- [4- (2- أدامنتيل كربامويل) -5- ثلاثي- بيوتيل – بيرازول -1- يل] حمض بنزويك 471 |
| JP2011518216A (ja) * | 2008-04-22 | 2011-06-23 | アストラゼネカ アクチボラグ | 置換ピリミジン−５−カルボキサミド |
| WO2011049520A1 (en) * | 2009-10-20 | 2011-04-28 | Astrazeneca Ab | Adamantyl iminocarbonyl-substituted pyrimidines as inhibitors of 1 1 betahsd1 |
-
2009
- 2009-02-03 SA SA109300090A patent/SA109300090B1/ar unknown
- 2009-02-03 CA CA2713409A patent/CA2713409A1/en not_active Abandoned
- 2009-02-03 KR KR1020107018287A patent/KR20100126306A/ko not_active Withdrawn
- 2009-02-03 EP EP09707161A patent/EP2244705A1/en not_active Withdrawn
- 2009-02-03 WO PCT/GB2009/050096 patent/WO2009098501A1/en not_active Ceased
- 2009-02-03 AU AU2009211215A patent/AU2009211215B2/en not_active Ceased
- 2009-02-03 UY UY031627A patent/UY31627A1/es not_active Application Discontinuation
- 2009-02-03 CN CN2009801037119A patent/CN101969946A/zh active Pending
- 2009-02-03 RU RU2010133483/04A patent/RU2010133483A/ru unknown
- 2009-02-03 JP JP2010544790A patent/JP2011510966A/ja not_active Withdrawn
- 2009-02-03 US US12/364,949 patent/US7951833B2/en not_active Expired - Fee Related
- 2009-02-03 MX MX2010008583A patent/MX2010008583A/es not_active Application Discontinuation
- 2009-02-04 TW TW098103551A patent/TW200946506A/zh unknown
- 2009-02-04 PE PE2009000164A patent/PE20091456A1/es not_active Application Discontinuation
- 2009-02-04 AR ARP090100364A patent/AR070560A1/es not_active Application Discontinuation
-
2010
- 2010-03-05 US US12/718,208 patent/US20110028529A1/en not_active Abandoned
- 2010-03-05 US US12/718,427 patent/US20110028530A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN101969946A (zh) | 2011-02-09 |
| MX2010008583A (es) | 2010-08-30 |
| AU2009211215A1 (en) | 2009-08-13 |
| CA2713409A1 (en) | 2009-08-13 |
| PE20091456A1 (es) | 2009-10-24 |
| US20110028529A1 (en) | 2011-02-03 |
| UY31627A1 (es) | 2009-08-31 |
| RU2010133483A (ru) | 2012-03-20 |
| WO2009098501A1 (en) | 2009-08-13 |
| TW200946506A (en) | 2009-11-16 |
| EP2244705A1 (en) | 2010-11-03 |
| US20090221660A1 (en) | 2009-09-03 |
| SA109300090B1 (ar) | 2011-10-03 |
| KR20100126306A (ko) | 2010-12-01 |
| US7951833B2 (en) | 2011-05-31 |
| US20110028530A1 (en) | 2011-02-03 |
| JP2011510966A (ja) | 2011-04-07 |
| AU2009211215B2 (en) | 2011-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070560A1 (es) | Formas cristalinas de acido 4-(4-(2-adamantilcarbamoil) -5-ter-butil-pirazol-1-il) benzoico 471 | |
| UY31774A (es) | Compuestos de 2-pirimidin-5- ilcarboxamida sustituidos | |
| CU20110162A7 (es) | Nueva forma cristalina vi de la agomelatina, preparación y uso de la misma | |
| DOP2014000133A (es) | Triazolopiridinas sustituidas | |
| CU20120084A7 (es) | Compuestos derivados de triazolopiridina sustituidos como inhibidores de la quinasa mps-1 y compuestos intermediarios para su preparación | |
| AR077242A1 (es) | Formas cristalinas del 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopropilamino]butiloxi}n-(metilsulfonil)acetamida, composiciones farmaceuticas que las contienen, metodo para prepararlas y uso de las mismas en el tratamiento de isquemias, insuficiencia coronaria y asma, entre otras enfermedades. | |
| PE20120083A1 (es) | Sal monotosilato del compuesto 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2, 3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo en su forma cristalina a | |
| UY33452A (es) | Triazolopiridinas sustituidas | |
| ECSP099571A (es) | Derivados pirazólicos como inhibidores de la 11-beta-hsd1 | |
| UY33491A (es) | ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?. | |
| ECSP088859A (es) | Nueva forma cristalina vi de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen | |
| UY33500A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
| ECSP109856A (es) | Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842 | |
| ECSP13013011A (es) | Triazolopiridinas | |
| IT1401087B1 (it) | Uso di alfa cheto acidi, o loro derivati, per rendere liscio il capello riccio, crespo od ondulato. | |
| AR096046A1 (es) | Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso | |
| AR096759A1 (es) | Formas sólidas de un inhibidor de quinasa macrocíclica | |
| AR088755A1 (es) | Formas solidas de un inhibidor de disociacion transtiretina | |
| WO2009040289A3 (en) | Biaryl sulfonamide derivatives | |
| MX2022015151A (es) | Procesos para preparar acido 3-(3-(3,5-dimetil-1h-pirazol-4-il)pro poxi)-4- 5-fluorobenzoico (ag-10), sus compuestos intermedios, y sales del mismo. | |
| CY1122596T1 (el) | Νεες φαρμακοτεχνικες μορφες (τριμεθοξυφαινυλαμινο)πυριμιδινυλιου | |
| UY32954A (es) | PIRIMIDINAS SUSTITUIDAS CON ADAMANTILIMINOCARBONILO COMO INHIBIDORES DE 11-ß-HSD1 826?. | |
| CL2012003497A1 (es) | Procedimiento para preparar el compuesto diácido 3,6,9-triaza-3,6,9-tris(carboximetil)-4-(4-etoxibencil)-undecanoico cristalino; su uso para preparar una formulación galénica del complejo de gadolinio de diacido 3,6,9-triaza-3,6,9-tris(carboximetil)-4-(4-etoxibencil)-undecanoico; y el compuesto con una pureza superior al 99%. | |
| CO6270318A2 (es) | Acido 4-[4-(2adamantilcarbomoil)-5-tert-butilpirazol -1-il]benzoico-465 | |
| BR112012022039B8 (pt) | composto do tipo éster de dibenzilideno sorbitol, processo para preparar o composto de fórmula (i), composição, método para o tratamento cosmético de substâncias queratínicas e uso de pelo menos um composto de fórmula (i) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |